ADCY7 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2657749	0.81	8/20
SCHEMBL2658721	0.74	8/20
SCHEMBL2658383	0.63	8/20
SCHEMBL2657546	0.61	8/20
SCHEMBL2657983	0.60	8/20
SCHEMBL2657082	0.74	7/20
SCHEMBL2657077	0.60	7/20
SCHEMBL1919194	0.53	7/20
SCHEMBL2653753	0.51	7/20
SCHEMBL2654576	0.51	7/20
SCHEMBL2655409	0.51	7/20
SCHEMBL2655997	0.49	7/20
SCHEMBL2656673	0.49	7/20
SCHEMBL2657984	0.64	6/20
SCHEMBL2658531	0.60	6/20
SCHEMBL2653428	0.58	6/20
SCHEMBL2653879	0.57	6/20
SCHEMBL2657305	0.52	6/20
SCHEMBL2656182	0.52	6/20
SCHEMBL2658725	0.51	6/20

Clinical trials — most relevant to ADCY7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Varenicline (Chantix™) for the Treatment of Alcohol Dependence	PHASE2	COMPLETED
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals	PHASE1/PHASE2	COMPLETED
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction	PHASE2	COMPLETED
Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease	PHASE2	ACTIVE_NOT_RECRUITING
Carbidopa-levodopa in Neovascular AMD	PHASE2	COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram	PHASE1	COMPLETED
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses	PHASE1	UNKNOWN
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.	PHASE1	COMPLETED
PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A	EARLY_PHASE1	COMPLETED
Caffeine Efficacy in ADCY5-related Dyskinesia	nan	UNKNOWN
Assessment of ADCY5-related Movement Disorders With Motion SENSors	nan	COMPLETED
Pilot Study on Caffeine Efficiency in ADCY5-related Dyskinesia	nan	COMPLETED
Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias	nan	COMPLETED
Natural History of Spinocerebellar Ataxia Type 7 (SCA7)	nan	RECRUITING
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Stress and Treatment Response in Puerto Rican Children With Asthma	nan	COMPLETED
The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients	nan	COMPLETED
PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow	nan	COMPLETED
The Effects of Tailored Judo Training and Nutritional Counseling on Physical Fitness and Body Composition in Children With Autism: A Study Including Blood Morphology and Genetic Analysis	nan	COMPLETED
Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan	nan	ENROLLING_BY_INVITATION
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease	nan	RECRUITING
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
Identification of Genetic Basis of Atrioventricular Conduction Defects: From Congenital Forms to Degenerative Forms	nan	UNKNOWN
Effect of Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl for Post-Operative Analgesia Following Laparoscopy in Pediatric Patients	nan	NOT_YET_RECRUITING
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a ADCY7 binder may also engage these)

Protein	Name	Similarity
P51829	—	1.000	P51829 →
Q29450	—	1.000	Q29450 →
Q80TL1	—	1.000	Q80TL1 →
Q91WF3	—	1.000	Q91WF3 →
ADCY2	Adenylate cyclase type 2	0.998	landscape →
ADCY4	Adenylate cyclase type 4 (EC 4.6.1.1) (ATP py	0.997	landscape →
P26769	—	0.996	P26769 →
ADCY3	Adenylate cyclase type 3	0.995	landscape →
P32870	—	0.995	P32870 →
ADCY1	Adenylate cyclase type 1	0.994	landscape →
P30804	—	0.994	P30804 →
P40146	—	0.994	P40146 →
ADCY6	Adenylate cyclase type 6 (EC 4.6.1.1) (ATP py	0.994	landscape →
P19754	—	0.993	P19754 →
P26770	—	0.993	P26770 →
O88444	—	0.993	O88444 →
ADCY8	Adenylate cyclase type 8	0.993	landscape →
P97490	—	0.991	P97490 →
Q01341	—	0.990	Q01341 →
Q03343	—	0.989	Q03343 →
P21932	—	0.989	P21932 →
Q8VHH7	—	0.989	Q8VHH7 →
Q9DGG6	—	0.988	Q9DGG6 →
P98999	—	0.987	P98999 →
Q09429	—	0.987	Q09429 →
ABCC8	ATP-binding cassette sub-family C member 8	0.986	landscape →
Q09427	—	0.986	Q09427 →
B0R0W9	—	0.985	B0R0W9 →
D3ZEY4	—	0.985	D3ZEY4 →
E9Q4S1	—	0.985	E9Q4S1 →